An Analysis of Cytokine Concentration in Open Abdominal Closure of Trauma Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02728609 |
Recruitment Status :
Completed
First Posted : April 5, 2016
Last Update Posted : April 5, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Abdominal Trauma | Device: ABThera vacuum device Device: Blue towel: vacuum pack device |
Elevated pro and anti-inflammatory cytokines have been implicated as markers for multi-system organ failure (MOF) and death in trauma patients. Abdominal surgery can raise the levels of these cytokines and may lead to elevated plasma levels of these inflammatory cytokines possibly leading to worsening patient prognosis. Patients in whom open abdominal closure is required are often the sickest of trauma patients. Two different temporary abdominal closure techniques are generally used at the Presley Memorial Trauma Center, one using the blue towel: vacuum pack technique and one using the commercially available ABThera vacuum device from Kinetic Concepts, Inc (KCI). This study is being conducted to determine if the ABThera temporary closure technique removes a greater amount of cytokines from the abdominal cavity possibly lessening the amount of systemic or plasma cytokines and thus decreasing the incidence of MOF and death in this very ill population of patients. Additionally, this study is being conducted to determine if the white blood cell count may be lower in patients with the least cytokine values and to also investigate protein loss in these patients. The depletion of body stores of protein due to an open abdomen has great nutritional and, therefore, healing implications.
Enrollment will include 40 subjects meeting eligibility criteria into this study. The study population will include 20 patients who were temporarily closed using the ABThera device and 20 who were temporarily closed using the blue towel: vacuum pack technique. Peritoneal fluid and blood will be collected in eligible subjects immediately upon arrival to the ICU following surgery and at 12, 24, 48 and 72 hours following placement. Peritoneal fluid will be collected from the drainage system into a Lukens trap. Blood will be collected from an existing intravenous or arterial line. The peritoneal fluid will be centrifuged, separated, and frozen at -80 degrees centigrade for analysis of cytokine/inflammatory markers, protein, and WBC count. The blood specimens will be centrifuged, separated, and frozen for cytokine/inflammatory marker analysis. Chemistry and hematology values completed as standard of care will be collected from the hospital chart along with general demographics, description of injuries, treatment modalities, and outcomes.
The first samples of blood and peritoneal fluid will be obtained immediately on arrival in the ICU when other labs are being drawn as standard of care. These samples will be put aside until consent can be obtained from the legally authorized representative or the subject himself. If the research subject and/or his legally authorized representative decide that the subject should not participate in the study, the sample will be destroyed and no additional study procedures will be obtained. If the legally authorized representative is not available within 12 hours of the initial specimen and the subject is unable to consider participation within 12 hours of the initial specimens, the subject will not be enrolled into the study, and samples obtained immediately on arrival to the ICU will be destroyed.
After all analyses are completed, comparison of the cytokine levels, WBC count, and protein extraction between the two vacuum methods will be completed and correlated to the patients' overall organ function.
Study Type : | Observational |
Actual Enrollment : | 40 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | An Analysis of Cytokine Concentration in Open Abdominal Closure of Trauma Patients |
Study Start Date : | March 2010 |
Actual Primary Completion Date : | January 2014 |
Actual Study Completion Date : | April 2014 |

Group/Cohort | Intervention/treatment |
---|---|
Blue towel: vacuum pack device
Trauma subjects undergoing temporary abdominal closure with vacuum pack technique
|
Device: Blue towel: vacuum pack device
This intervention uses operating room towels and the application of suction to temporarily close the abdomen following surgery. |
ABThera abdominal closure
Trauma subjects undergoing temporary abdominal closure with the commercially available ABThera vacuum device
|
Device: ABThera vacuum device
This intervention uses a commercially available vacuum device to temporarily close the abdomen following surgery.
Other Name: Commercially available vacuum pack closure |
- Change in cytokine levels over 72 hours in peritoneal fluid in each enrolled subject [ Time Frame: Change in cytokine levels over 72 hours following placement of the device ]Fluid will be obtained from the collection portion of the device into a Lukens trap. Fluid will be centrifuged into separate specimens and frozen at -80 degrees centigrade prior to analysis. Specimens will be analyzed using standard laboratory process.
- Change in white blood cell count in peritoneal fluid over 72 hours following placement of the device in each enrolled subject [ Time Frame: Serial samples obtained over 72 hours following placement of the device ]Fluid will be obtained from the collection portion of the device into a Lukens trap. Fluid will be centrifuged into separate specimens and frozen at -80 degrees centigrade prior to analysis. Specimens will be analyzed using standard laboratory process.
- Change in protein content in peritoneal fluid over 72 hours following placement of the device in each enrolled subject [ Time Frame: Serial samples obtained over 72 hours following placement of the device ]Fluid will be obtained from the collection portion of the device into a Lukens trap. Fluid will be centrifuged into separate specimens and frozen at -80 degrees centigrade prior to analysis. Specimens will be analyzed using standard laboratory process.
- Change in cytokine levels in serum samples over 72 hours following placement of the device in each enrolled subject [ Time Frame: Serial samples obtained over 72 hours following placement of the device ]Serum samples will be collected for an indwelling intravenous catheter, centrifuged into separate specimens and frozen for cytokine/inflammatory marker analysis. Specimens will be analyzed using standard laboratory process.
Biospecimen Retention: None Retained

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- 18 to 75 years of age who have been admitted following abdominal trauma and require open laparotomy
- Those who are closed using either the blue towel: vacuum pack method or the ABThera vacuum device
- Those who can be enrolled within 12 hours of placement of temporary abdominal closure
Exclusion Criteria:
- Those who cannot give informed consent and do not have a Legally Authorized Representative available
- Prisoners are excluded
- Pregnant women are excluded
- Those under 18 years of age and older than 75 years of age
- Those who do not require temporary abdominal closure using either the blue towel: vacuum pack technique or with the ABThera vacuum device.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02728609
Principal Investigator: | Timothy C. Fabian, MD | University of Tennessee Health Science Center |
Responsible Party: | Timothy C. Fabian, M.D., MD, Harwell Wilson Alumni Professor, University of Tennessee |
ClinicalTrials.gov Identifier: | NCT02728609 |
Other Study ID Numbers: |
10-00739-FB |
First Posted: | April 5, 2016 Key Record Dates |
Last Update Posted: | April 5, 2016 |
Last Verified: | March 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Wounds and Injuries Abdominal Injuries |